Skip to main content

Advertisement

SpringerLink
Log in

Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the vision-related quality of life (VR-QOL) and visual function in patients undergoing intravitreal injection of bevacizumab (IVB) for persistent diabetic macular edema (DME) after vitrectomy.

Methods

This institutional study enrolled 20 consecutive patients (20 eyes) who had received 1.25 mg IVB for persistent macular edema after vitrectomy for DME at least 3 months previously. Visual function and VR-QOL were measured before, and 1 and 3 months after IVB. Measurements included the logarithm of the minimum angle of resolution (logMAR), best corrected visual acuity (BCVA), letter contrast sensitivity, severity of metamorphopsia using M-CHARTS, central retinal thickness using optical coherence tomography, and VR-QOL with the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25).

Results

One month after IVB, statistically significant improvements were observed in central retinal thickness, letter contrast sensitivity, and the VFQ-25 “mental health” subscale score (P < 0.05, Dunnett test). LogMAR BCVA, metamorphopsia, and the VFQ-25 composite score did not improve significantly. Three months after IVB, there were no significant improvements in any parameters examined.

Conclusions

Intravitreal bevacizumab injection for persistent DME after vitrectomy temporarily improved central retinal thickness, contrast sensitivity, and the psychometric aspect of the VR-QOL, but these effects did not last for over 3 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103:1796–806.

    Article  Google Scholar 

  2. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol. 2005;139:290–4.

    Article  CAS  PubMed  Google Scholar 

  3. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–7.

    Article  PubMed  Google Scholar 

  4. Rosenblatt BJ, Shah GK, Sharma S, Bakal J. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch Clin Exp Ophthalmol. 2005;243:20–5.

    Article  PubMed  Google Scholar 

  5. Recchia FM, Ruby AJ, Carvalho Recchia CA. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am J Ophthalmol. 2005;139:447–54.

    Article  PubMed  Google Scholar 

  6. Abe S, Yamamoto T, Kashiwagi Y, Kirii E, Goto S, Yamashita H. Three-dimensional imaging of the inner limiting membrane folding on the vitreomacular interface in diabetic macular edema. Jpn J Ophthalmol. 2013;57:553–62.

    Article  PubMed  Google Scholar 

  7. Tamura K, Yokoyama T, Ebihara N, Murakami A. Histopathologic analysis of the internal limiting membrane surgically peeled from eyes with diffuse diabetic macular edema. Jpn J Ophthalmol. 2012;56:280–7.

    Article  PubMed  Google Scholar 

  8. Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function after vitrectomy for various vitreoretinal disorders. Investig Ophthalmol Vis Sci. 2010;51:744–51.

    Article  Google Scholar 

  9. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M et al Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743–50.

    Article  Google Scholar 

  10. Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27:1187–95.

    Article  PubMed  Google Scholar 

  11. Arimura E, Matsumoto C, Okuyama S, Takada S, Hashimoto S, Shimomura Y. Quantification of metamorphopsia in a macular hole patient using M-CHARTS. Acta Ophthalmol Scand. 2007;85:55–9.

    Article  PubMed  Google Scholar 

  12. Matsumoto C, Arimura E, Okuyama S, Takada S, Hashimoto S, Shimomura Y. Quantification of metamorphopsia in patients with epiretinal membranes. Investig Ophthalmol Vis Sci. 2003;44:4012–6.

    Article  Google Scholar 

  13. Pelli DG, Robson G, Wilkins AJ. The designed of a new letter chart for measuring contrast sensitivity. Clin Vis Sci. 1988;2:187–99.

    Google Scholar 

  14. Maeda N, Sato S, Watanabe H, Inoue Y, Fujikado T, Shimamura Y, et al. Prediction of letter contrast sensitivity using videokeratographic indices. Am J Ophthalmol. 2000;129:759–63.

    Article  CAS  PubMed  Google Scholar 

  15. Elliott DB, Bullimore MA, Bailey IL. Improving the reliability of the Pelli-Robson contrast sensitivity test. Clin Vis Sci. 1991;6:471–5.

    Google Scholar 

  16. Mangione CM, Lee PP, Gutierrez PR, Spitzer K, Berry S, Hays RD. National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050–8.

    Article  CAS  PubMed  Google Scholar 

  17. Suzkamo Y, Oshika T, Yuzawa M, Tokuda Y, Tomidokoro A, Oki K, et al. Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version. Health Qual Life Outcomes. 2005;3:65.

    Article  Google Scholar 

  18. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007;27:557–66.

    Article  PubMed  Google Scholar 

  19. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247:147–63.

    Article  PubMed  Google Scholar 

  20. Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Investig Ophthalmol Vis Sci. 2012;53:5877–80.

    Article  CAS  Google Scholar 

  21. Chou TH, Wu PC, Kuo JZ, Lai CH, Kuo CN. Relationship of diabetic macular oedema with glycosylated haemoglobin. Eye (Lond). 2009;23:1360–3.

    Article  CAS  Google Scholar 

  22. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126:1707–15.

    Article  PubMed  Google Scholar 

  23. Itoh-Tanimura M, Hirakata A, Itoh Y, Sano ME, Inoue M, Ishida H. Relationship between compliance with ophthalmic examinations preoperatively and visual outcome after vitrectomy for proliferative diabetic retinopathy. Jpn J Ophthalmol. 2012;56:481–7.

    Article  PubMed  Google Scholar 

  24. Mehta S, Blinder KJ, Shah GK, Kymes SM, Schlief SL, Grand MG. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010;41:323–9.

    Article  PubMed  Google Scholar 

  25. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124–6.

    Article  CAS  PubMed  Google Scholar 

  26. Amsler M. Earliest symptoms of disease of the macula. Br J Ophthalmol. 1953;37:521–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction. Arch Ophthalmol. 1966;76:646–61.

    Article  CAS  PubMed  Google Scholar 

  28. Okamoto F, Sugiura Y, Okamoto Y, Hiraoka T, Oshika T. Associations between metamorphopsia and foveal microstructure in patients with epiretinal membrane. Investig Ophthalmol Vis Sci. 2012;53:6770–5.

    Article  Google Scholar 

  29. Owsley C, Sloane ME. Contrast sensitivity, acuity, and the perception of “real-world” targets. Br J Ophthalmol. 1987;71:791–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Lennerstrand G, Ahlstrom CO. Contrast sensitivity in macular degeneration and the relation to subjective visual impairment. Acta Ophthalmol (Copenh). 1989;67:225–33.

    Article  CAS  Google Scholar 

  31. Leat SJ, Woodhouse JM. Reading performance with low vision aids: relationship with contrast sensitivity. Ophthalmic Physiol Opt. 1993;13:9–16.

    Article  CAS  PubMed  Google Scholar 

  32. Rubin GS, Roche KB, Prasada-Rao P, Fried LP. Visual impairment and disability in older adults. Optom Vis Sci. 1994;71:750–60.

    Article  CAS  PubMed  Google Scholar 

  33. Okamoto F, Okamoto Y, Hiraoka T, Oshika T. Vision-related quality of life and visual function after retinal detachment surgery. Am J Ophthalmol. 2008;146:85–90.

    Article  PubMed  Google Scholar 

  34. Nagasawa T, Naito T, Matsushita S, Sato H, Katome T, Shiota H. Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular edema. J Med Invest. 2009;56:111–5.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Publication of this article was supported by the Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Conflicts of interest

Y. Okamoto, None; F. Okamoto, None; T. Hiraoka, None; T. Oshika; None.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8575, Japan

    Yoshifumi Okamoto, Fumiki Okamoto, Takahiro Hiraoka & Tetsuro Oshika

Authors
  1. Yoshifumi Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumiki Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiro Hiraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tetsuro Oshika
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshifumi Okamoto.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okamoto, Y., Okamoto, F., Hiraoka, T. et al. Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy. Jpn J Ophthalmol 58, 369–374 (2014). https://doi.org/10.1007/s10384-014-0323-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-014-0323-7

Keywords

Search

Navigation